Clinical trials: Immunotherapy, Allergen
Allergic Rhinitis Due to House Dust Mite
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
The purpose of this study is to investigate the safety and tolerability of different doses of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust mite-associated allergic rhinitis.
- Trial name
- NCT01919554
- Testing
- 500 IR house dust mites allergen extract tablet, 1000 IR house dust mites allergen extract tablet, 1500 IR house dust mites allergen extract tablet
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Stallergenes Greer
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.
- Trial name
- NCT01700192
- Testing
- MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets
- Volunteers
- 1,482 people
- Sponsor
- ALK-Abelló A/S
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Allergy
Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
A phase III study to evaluate the efficacy and safety of SLIT for grass pollen allergens compared with placebo for reduction of symptoms and rescue medication usage in children.
- Trial name
- NCT00409409
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Germany
- Volunteers
- 278 people
- Sponsor
- Stallergenes Greer
Allergy, Immune Tolerance
Effect of Intralymphatic Immunotherapy
The investigators want to investigate whether specific immunotherapy can be delivered directly into a lymph node. The investigators think that a direct introduction of allergen to the antigen presenting cells in the lymph node a…
- Conditions
- Allergy, Immune Tolerance, Injection Site Discomfort
- Trial name
- NCT02255604
- Testing
- Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml., 0.1 ml Isoton saline
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- University of Aarhus
Asthma, Allergic Sensitization
Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the…
- Trial name
- GPAC (NCT00346398)
- Testing
- Oral mucosal immunoprophylaxis (OMIP)
- Where
- 3 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Rhinoconjunctivitis, Grass Pollen Allergy
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
The primary objective of this study is to assess whether the combination of grass allergen sublingual immunotherapy (SLIT) and dupilumab for 2 years is more effective than double placebo in suppressing the nasal allergen…
- Trial name
- GRADUATE (NCT04502966)
- Testing
- Dupixent®, Grazax®
- Where
- United Kingdom
- Volunteers
- 199 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Birch Pollen Allergy
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
Study aiming to evaluate the efficacy of a 2-month pre-seasonal treatment with an AllerT 50 µg or 100 µg maintenance dose administered in previous study AN004T in reducing symptoms of allergic rhinoconjunctivitis during the 2nd…
- Trial name
- NCT02143583
- Where
- 22 sites in Denmark, France and 5 more
- Volunteers
- 196 people
- Sponsor
- Anergis
Hen Egg Allergy
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
- Trial name
- NCT04056299
- Testing
- AR201 powder
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergy;Food, Allergy to Shrimp
Food Allergen OIT for Shrimp and Cashew
A prospective Phase 2, single-center, single-allergen OIT of cashew or shrimp in participants with proven allergies to either cashew or shrimp, respectively.
- Conditions
- Allergy;Food, Allergy to Shrimp, Allergy to Cashew Nut (Disorder)
- Trial name
- MOTIF (NCT03504774)
- Testing
- Cashew or Shrimp Oral Immunotherapy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sayantani B. Sindher
Peanut Hypersensitivity, Food Hypersensitivity
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies.
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
- Trial name
- NCT01904604
- Testing
- Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Rhinitis Due to Grass Pollens
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.
- Trial name
- NCT00955825
- Testing
- 300 IR
- Where
- 19 sites in United States
- Volunteers
- 473 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis
Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
About 45 million people in Europe have allergic rhinitis (hay fever) - inflammation of the nasal passages causing sneezing, runny nose, nasal congestion, itching and tearing of the eyes.
- Trial name
- Pollen+ (NCT02005627)
- Testing
- Grazax
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Immunologic Desensitization
Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy
The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
- Trial name
- NCT02676765
- Testing
- allergen extract tablet
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
ARTEMIS Peanut Allergy In Children
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
- Trial name
- ARTEMIS (NCT03201003)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 175 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
- Trial name
- NCT03292484
- Testing
- AR101
- Where
- 93 sites in United States, Canada and 8 more
- Volunteers
- 911 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergic Rhinitis Due to Dust Mite
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
The purpose of this study is to assess the efficacy of one dose of sublingual immunotherapy (SLIT) administered to children and adolescents as allergen-based tablets once daily over a period of 24 months over 3 years compared to…
- Trial name
- NCT01199133
- Testing
- 300 IR house dust mites allergen extract tablet
- Volunteers
- 471 people
- Sponsor
- Stallergenes Greer
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.